Evidence map›Paper›PMID 35621196›Full record

ArticleJournal of the American Heart Association2022

Modeling the Progression of Cardiac Catecholamine Deficiency in Lewy Body Diseases.

David S Goldstein, Mark J Pekker, Patti Sullivan, Risa Isonaka, Yehonatan Sharabi

Open access · goldAbstract read
In one paragraph

Article in Journal of the American Heart Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Putamen dopamine synthesis, vesicular storage, and metabolism in Parkinson disease.medRxiv : the preprint server for health sciences · 2026
    Article
  3. Preclinical Catecholaminergic Biomarkers of Central Lewy Body Diseases.Journal of clinical neurology (Seoul, Korea) · 2026
    Review
  4. Multitracer PET to Assess Cardiac Sympathetic Innervation and Vesicular Storage in Lewy Body Diseases.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Article
  5. "Body-first" dementia with Lewy bodies.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2025
    Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

David S GoldsteinAutonomic Medicine Section Clinical Neurosciences Program Division of Intramural Research National Institute of Neurological Disorders and StrokeNational Institutes of Health Bethesda MD.ORCID 0000-0002-5709-9940
Mark J PekkerMathematical Sciences University of Alabama at Huntsville Huntsville AL.ORCID 0000-0003-0845-5889
Patti SullivanAutonomic Medicine Section Clinical Neurosciences Program Division of Intramural Research National Institute of Neurological Disorders and StrokeNational Institutes of Health Bethesda MD.
Risa IsonakaAutonomic Medicine Section Clinical Neurosciences Program Division of Intramural Research National Institute of Neurological Disorders and StrokeNational Institutes of Health Bethesda MD.
Yehonatan SharabiTel Aviv University Sackler Faculty of Medicine and Chaim Sheba Medical CenterTel HaShomer Israel.
National Institutes of Health · USTel Aviv University · ILUniversity of Alabama in Huntsville · US

Funding

Biomarkers of Parkinson Disease and Related DisordersZIANS003034 · NINDS · NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE · PI GOLDSTEIN, DAVID · 2009 to 2025
$22.8M
Mechanisms of Parkinson Disease and Related DisordersZIANS003033 · NINDS · NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE · PI GOLDSTEIN, DAVID · 2009 to 2022
$8.2M
Treatment of Catecholaminergic NeurodegenerationZIANS003125 · NINDS · NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE · PI GOLDSTEIN, DAVID · 2011 to 2022
$3.2M
6 · The paper itself

Abstract

Background Lewy body diseases (LBDs) feature deficiency of the sympathetic neurotransmitter norepinephrine in the left ventricular myocardium and sympathetic intra-neuronal deposition of the protein alpha-synuclein (αS). LBDs therefore are autonomic synucleinopathies. Computational modeling has revealed multiple functional abnormalities in residual myocardial sympathetic noradrenergic nerves in LBDs, including decreased norepinephrine synthesis, vesicular storage, and recycling. We report an extended model that enables predictions about the progression of LBDs and effects of genetic predispositions and treatments on that progression. Methods and Results The model combines cardiac sympathetic activation with autotoxicity mediated by the dopamine metabolite 3,4-dihydroxyphenylacetaldehyde. We tested the model by its ability to predict longitudinal empirical data based on cardiac sympathetic neuroimaging, effects of genetic variations related to particular intra-neuronal reactions, treatment by monoamine oxidase inhibition to decrease 3,4-dihydroxyphenylacetaldehyde production, and post-mortem myocardial tissue contents of catecholamines and αS. The new model generated a triphasic decline in myocardial norepinephrine content. This pattern was confirmed by empirical data from serial cardiac

Indexed as

Lewy Body DiseaseParkinson DiseaseCatecholaminesDopamineHumansLewy BodiesMonoamine OxidaseNorepinephrineSympathetic Nervous SystemTomography, X-Ray ComputedCatecholaminesDopamineMonoamine OxidaseNorepinephrinecatecholaldehydecatecholaminecomputational modelingDOPAL, Lewy bodynorepinephrinesympathetic nervous system

Identifiers

PMID35621196
PMCPMC9238705
OpenAlexW4281633625

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.